Brainstorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BCLI
  • CUSIP: N/A
  • Web: www.brainstorm-cell.com
Capitalization:
  • Market Cap: $75.12 million
  • Outstanding Shares: 18,687,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $3.33
  • 52 Week Range: $2.06 - $5.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.83
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.53 per share
  • Price / Book: 7.58
Profitability:
  • EBIDTA: ($5,010,000.00)
  • Return on Equity: -46.80%
  • Return on Assets: -41.19%
Debt:
  • Current Ratio: 9.56%
  • Quick Ratio: 9.56%
Misc:
  • Average Volume: 203,919 shs.
  • Beta: 1.81
  • Short Ratio: 3.24
 

Frequently Asked Questions for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) posted its earnings results on Monday, May, 15th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.20. View Brainstorm Cell Therapeutics' Earnings History.

Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2017?

1 brokerages have issued 12-month price targets for Brainstorm Cell Therapeutics' stock. Their predictions range from $8.00 to $8.00. On average, they expect Brainstorm Cell Therapeutics' stock price to reach $8.00 in the next year. View Analyst Ratings for Brainstorm Cell Therapeutics.

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:

  • Irit Arbel, Chairman of the Board
  • Chaim Lebovits, Chief Executive Officer
  • Yoram Bibring CPA, Chief Financial Officer, Treasurer
  • Ralph Kern, Chief Operating Officer and Chief Medical Officer
  • Uri Yablonka, Executive Vice President, Chief Business Officer, Director
  • Alla Patlis, Controller
  • June S. Almenoff M.D. Ph.D., Independent Director
  • Arturo Araya, Independent Director
  • Mordechai Friedman, Independent Director
  • Alon Pinkas, Independent Director

Who owns Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.42%), Geode Capital Management LLC (0.39%) and KCG Holdings Inc. (0.22%). Company insiders that own Brainstorm Cell Therapeutics stock include International Holdings Ltd Acc, Malcolm S Taub, Robert G L Shorr and Yoram Bibring. View Institutional Ownership Trends for Brainstorm Cell Therapeutics.

Who bought Brainstorm Cell Therapeutics stock? Who is buying Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC and KCG Holdings Inc.. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include International Holdings Ltd Acc and Yoram Bibring. View Insider Buying and Selling for Brainstorm Cell Therapeutics.

How do I buy Brainstorm Cell Therapeutics stock?

Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $4.02.


MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)
Community Ranking:  4.9 out of 5 (   )
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (99.00% upside)

Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Maxim GroupSet Price TargetBuy$8.00MediumView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Earnings History by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.30)($0.10)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.07)($0.03)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
3/10/2016Q415($0.15)($0.07)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.12)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Current Year EPS Consensus Estimate: $-0.79 EPS
Next Year EPS Consensus Estimate: $-1.05 EPS

Dividends

Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Insider Ownership Percentage: 23.70%
Institutional Ownership Percentage: 9.22%
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Source:
DateHeadline
prnewswire.com logoBrainStorm to Present at Cell & Gene Exchange Conference in Washington DC - PR Newswire (press release)
www.prnewswire.com - May 22 at 3:48 PM
finance.yahoo.com logoBrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
finance.yahoo.com - May 22 at 10:50 AM
prnewswire.com logoBrainStorm Initiated Technology Transfer to City of Hope for U.S. ... - PR Newswire (press release)
www.prnewswire.com - May 16 at 3:56 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) Releases Earnings Results, Beats Estimates By $0.20 EPS
www.americanbankingnews.com - May 16 at 3:48 PM
finance.yahoo.com logoBrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
finance.yahoo.com - May 16 at 12:21 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) PT Set at $8.00 by Maxim Group
www.americanbankingnews.com - May 15 at 3:14 PM
seekingalpha.com logoBrainStorm Cell reports Q1 results
seekingalpha.com - May 15 at 8:52 AM
finance.yahoo.com logoBrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 15 at 8:52 AM
finance.yahoo.com logoBCLI: Approval of Edaravone Shows FDA’s Eagerness to Approve New Treatments for ALS
finance.yahoo.com - May 8 at 3:47 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - May 8 at 12:00 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics (BCLI) Getting Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 12:46 PM
prnewswire.com logoBrainStorm to Present at Two Scientific Conferences in May - PR Newswire (press release)
www.prnewswire.com - May 1 at 3:51 PM
finance.yahoo.com logoBrainStorm to Present at Two Scientific Conferences in May
finance.yahoo.com - May 1 at 9:16 AM
americanbankingnews.com logoBrainstorm Cell Therapeutics (BCLI) Earns Daily Media Sentiment Rating of 0.56
www.americanbankingnews.com - April 25 at 9:37 AM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) Given a $8.00 Price Target at Maxim Group
www.americanbankingnews.com - April 22 at 10:14 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics (BCLI) Receiving Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 12:01 PM
bizjournals.com logoBrainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
www.bizjournals.com - April 20 at 8:56 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Announces Publication of NurOwn Autism Research Study in Journal Behavioural ... - StreetInsider.com
www.streetinsider.com - April 20 at 3:56 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Announces Publication of NurOwn Autism Research Study in Journal Behavioural Brain Research
www.streetinsider.com - April 19 at 9:10 PM
seekingalpha.com logoBrainstorm Cell Therapeutics Set To Begin Phase 3 In Amyotrophic Lateral Sclerosis
seekingalpha.com - April 19 at 11:37 AM
finance.yahoo.com logoBrainStorm Announces Publication of NurOwn® Autism Research Study
finance.yahoo.com - April 19 at 11:37 AM
americanbankingnews.com logoBrainstorm Cell Therapeutics (BCLI) Receiving Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - April 18 at 1:02 PM
americanbankingnews.com logoShort Interest in Brainstorm Cell Therapeutics Inc (BCLI) Declines By 3.5%
www.americanbankingnews.com - April 17 at 12:38 PM
americanbankingnews.com logoZacks: Analysts Expect Brainstorm Cell Therapeutics Inc (BCLI) Will Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - April 17 at 10:43 AM
seekingalpha.com logoBrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate
seekingalpha.com - April 7 at 3:48 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals
finance.yahoo.com - April 7 at 8:22 AM
finance.yahoo.com logoBCLI: Phase 3 Trial of NurOwn® in ALS to Initiate in 2Q17
finance.yahoo.com - March 31 at 3:58 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) PT Raised to $8 at Maxim Group - StreetInsider.com
www.streetinsider.com - March 31 at 2:19 AM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - March 30 at 10:07 PM
finance.yahoo.com logoBrainStorm Announces Financial Results for 2016 and Provides Business Update
finance.yahoo.com - March 30 at 2:12 AM
finance.yahoo.com logoBrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
finance.yahoo.com - March 22 at 4:24 PM
americanbankingnews.com logoBrainstorm Cell Therapeutics Inc (BCLI) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - March 14 at 11:30 AM
biz.yahoo.com logoBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors
biz.yahoo.com - March 7 at 10:27 AM
us.rd.yahoo.com logoBrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
us.rd.yahoo.com - March 6 at 10:57 AM
us.rd.yahoo.com logoIsrael's BrainStorm names Biogen senior executive Kern as COO
us.rd.yahoo.com - March 6 at 10:57 AM
biz.yahoo.com logoBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements
biz.yahoo.com - March 2 at 4:28 PM
finance.yahoo.com logoBrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product
finance.yahoo.com - March 1 at 7:49 AM
finance.yahoo.com logoBrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
finance.yahoo.com - February 27 at 10:42 AM
finance.yahoo.com logoBCLI: Seeking Early Regulatory Approval in Canada for NurOwn® in ALS
finance.yahoo.com - February 24 at 12:59 PM
finance.yahoo.com logoBiotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics
finance.yahoo.com - February 23 at 3:51 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Signs Agreement with CCRM to Support Market Authorization Request for NurOwn in Canada
www.streetinsider.com - February 21 at 4:04 PM
investopedia.com logoBrainStorm Seeks ALS Drug Nod In Canada (BCLI)
www.investopedia.com - February 21 at 4:04 PM
us.rd.yahoo.com logoBrainStorm seeks early approval for stem cell treatment in Canada
us.rd.yahoo.com - February 21 at 4:04 PM
us.rd.yahoo.com logoBrainStorm Seeking Approval To Distribute NurOwn® in Canada
us.rd.yahoo.com - February 21 at 4:04 PM
us.rd.yahoo.com logo7:06 am Brainstorm Cell Therapeutics signs an agreement w/ CCRM to support the market authorization request for NurOwn
us.rd.yahoo.com - February 21 at 4:04 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Signs Agreement with CCRM to Support Market Authorization Request for ... - StreetInsider.com
www.streetinsider.com - February 21 at 11:45 AM
investopedia.com logoBrainStorm Seeks ALS Drug Approval In Canada
www.investopedia.com - February 21 at 11:45 AM
finance.yahoo.com logoCity of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial
finance.yahoo.com - February 16 at 8:46 AM
prnewswire.com logoBrainStorm CEO to Present at the BIO CEO & Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 7 at 1:55 AM
finance.yahoo.com logoBrainStorm CEO to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 3:51 PM

Social

Chart

Brainstorm Cell Therapeutics (BCLI) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff